$ATRA SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of inducement awards to Jakob Dupont, its Executive Vice President, Global Head of Research & Development.
The compensation committee of Atara’s board of directors granted Dr. Dupont restricted stock units to acquire 46,250 shares of Atara’s common stock under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, effective as of May 14, 2020. The restricted stock units were granted as an inducement material to Dr. Dupont entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The compensation committee also granted Dr. Dupont a stock option to purchase 277,500 shares of Atara’s common stock under the Atara Biotherapeutics, Inc. 2014 Equity Inventive Plan, as amended, effective as of May 14, 2020. The stock option has a ten-year term and an exercise price of $9.58, equal to the per share closing price of Atara's common stock as reported by Nasdaq on May 14, 2020.